A phase IIa multicenter, randomized, double-blind, placebo -controlled, parallel group study of RWJ-445380 cathepsin-S inhibitor in patients with active rheumatoid arthritis despite methotrexate therapy.

Trial Profile

A phase IIa multicenter, randomized, double-blind, placebo -controlled, parallel group study of RWJ-445380 cathepsin-S inhibitor in patients with active rheumatoid arthritis despite methotrexate therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs RWJ 445380 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 22 Jan 2009 Planned number of patients changed from 240 to 259 as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Added affiliate and sponsor (Johnson and Johnson) from clinicaltrials.gov record.
    • 01 Oct 2008 Added affiliate and sponsor (Johnson and Johnson) from clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top